Editors

BioWorld's News Director, Lynn Yoffee, leads a team of journalists from around the world that produces daily insider intelligence on key business, scientific, clinical and regulatory news covering the development of innovative human therapeutics and medical technologies. Under her direction, BioWorld has won dozens of awards for excellence in journalism from the Specialized Information Publishing Association. During her tenure with BioWorld  (1994-1997,  2007-present), she has guided the development of special series and investigative reports on key industry trends ranging from the lack of diversity in clinical trials to the burgeoning biosimilars sector and to the explosion of digital health. Yoffee started her career as a newspaper reporter and later moved into health care and medical science publishing for B2B and consumer audiences.

Jennifer Boggs joined the BioWorld group in 2004 as a staff writer after working for several years in newspapers. She was promoted to the position of assistant managing editor in 2008 and in 2011 was appointed as BioWorld's managing editor. Boggs is the driving force behind BioWorld's daily news cycle, coordinating coverage of breaking news, analysis, conferences and special series. Importantly, as the volume of news has increased over the years, she keeps the editorial team focused on the most innovative therapeutics in development.

Holland Johnson is the executive editor of BioWorld MedTech. He has more than 15 years of editorial and reporting experience, including the last 12 years in the newsletter industry covering medical technology, home health care and clinical advances in oncology and women's health. Prior to that, Johnson was a beat reporter for the Athens Observer.

Anette Breindl, PhD is the senior science editor at BioWorld, where she oversees the coverage of preclinical research. She has been with BioWorld since 2004, after starting her career in science communications at Atkins + Associates, a precursor firm to Canale Communications. She has also worked as a freelance writer for U.S. and German publications and co-authored several peer-reviewed papers. Breindl earned her PhD from the Leibniz Institute for Neurobiology in Magdeburg, Germany. Breindl also teaches science communications at the University at Albany, where she is a visiting scholar.

Peter Winter is a science journalist based in Ottawa, Ontario. He has been writing about and analyzing the progress of the global biotech industry since the early 1980s. He joined BioWorld in 2012 as the editor of BioWorld Insight, a weekly newsletter providing in-depth analysis on the key trends in the sector. Winter monitors the business and financial developments shaping the industry and has created several unique tracking indices that chart the collective equity performances of biopharmaceutical companies included in each index.

Mark McCarty has served as the regulatory editor for BioWorld MedTech since 2006. He covers FDA's regulation and enforcement activities for devices and diagnostics, but also provides in-depth insight into Medicare and private payer coverage and reimbursement. McCarty's portfolio at BioWorld MedTech includes medical device advisory committees, congressional hearings and medical specialty society meetings. Previously McCarty served as the managing editor for two publications by the Washington Information Source (WIS), Inspection Monitor and Warning Letter Bulletin, and was a contributing writer for WIS's Validation Times.

Mari Serebrov joined BioWorld in 2011 as regulatory editor, following a long career in the media, academia and a state agency, which gave her first-hand experience in dealing with state and federal regulations. In her writing for newspapers, radio and television, she covered health care from many angles. At BioWorld, she provides in-depth coverage of drug pricing, patents, biosimilars and other regulatory issues for BioWorld.

BioWorld News Editor Michael Fitzhugh works to help readers understand the significance and drivers behind daily life sciences headlines. He joined the team as a staff writer for BioWorld in 2014 after contributing to and editing several in-depth annual reports about health care's ever-changing landscape.

Writers

Bernard Banga, of Paris, has contributed to BioWorld MedTech team since 2015. For more than 20 years, he has covered the medical device industry in France and the rest of the European Union.

Annette Boyle has contributed to BioWorld MedTech since early 2019. She has covered biotech and the business of medicine for 15 years, providing in-depth reports and daily coverage for a range of U.S.-based B2B publications. Before pursuing a writing career, Boyle served as national director of marketing for a predecessor firm to Dentons, one of the world's largest law firms, and as a regional director of marketing for Ernst & Young.  

Meg Bryant is a staff writer for BioWorld MedTech. She has spent more than 30 years covering medical devices, pharmaceuticals and, more recently, digital health, both from a regulatory and business perspective. Before joining Clarivate Analytics in May 2019, she held editorial and reporting positions at FDAnews, Faulkner & Gray and F-D-C Reports, where she helped to launch the Beige Sheet, covering reimbursement policy. Bryant's articles have appeared in Healthcare Dive, New Physician and The Washington Post, among other publications.

Karen Carey is BioWorld's analyst who oversees all biopharma and medical technology data, and writes about financial, deal-making, clinical, scientific and regulatory industry trends. Her analytics incorporate two decades of data gathered from industry publications, experts, conferences and documents, and provide historical perspectives and visual insights of where the industries are heading. She first began working for BioWorld as a staff writer in 1999.

Shannon Ellis is a Canadian writer specializing in life science innovation and doing business in China. She has been a staff writer for BioWorld, covering China's emerging biopharma industry from Shanghai since 2013. Her writing has also been featured in Nature Biotechnology, Nature and The Financial Post. In addition, Ellis collects CEO-level insights for IMA Asia in Shanghai. Ellis graduated from McGill University in East Asian Studies and speaks and reads Mandarin. She is now based in Toronto.

After training in medical laboratory technology at the University of Oxford, John Fox’s research career took him to St Mary’s Hospital Medical School in London and subsequently to the University of Hong Kong, where he helped to establish the territory’s first IVF Unit at Hong Kong University’s Queen Mary Hospital. Later he transitioned to medical publishing in Hong Kong, eventually becoming the editor in chief of Medimedia Asia Ltd., which included Asian Medical News, the SE Asia edition of JAMA and Obstetrics and Gynecology. Fox has been a staff writer for BioWorld, mainly covering Asia, since 2014. He majored in applied biology and physiology at the Universities of Sussex and Leeds, where he also studied pharmacology and immunology.

David Godkin, of Toronto, has been a science and medical technologies writer for more than 20 years. In that time, he has written on emerging medical technologies in every province across Canada. His focus is on the science underpinning the development of medical devices, their practical application in health care and business strategies for bringing them to the global marketplace. He began writing for BioWorld MedTech in 2003.

Sergio Held is a Colombian-German journalist based out of Bogota, Colombia. He has been writing for BioWorld and BioWorld MedTech since 2014. He previously lived in Hong Kong and Barcelona. Held also produces radio and TV content from Bogota for national and international media outlets.

Alex Ho researches and writes for BioWorld and BioWorld MedTech on issues of finance, business and health care out of Hong Kong. He contributes to multiple publications and organizations including several real-time financial news wires, accounting firms and local news media. Ho has years of experience working as a due diligence analyst and financial market research analyst.

David Ho has been writing for BioWorld and BioWorld MedTech since 2017. He is based in Hong Kong and focuses on Asian markets. He has 12 years of writing experience and his work spans a range of sectors.

Vinod Kamalakannan is BioWorld's analyst who manages numerous databases of information focused on biopharma and medical technology deals, financings, product approvals and clinical results. He received both bachelor's and master's degrees in biochemistry from the University of Madras. A Clarivate employee since 2012 currently based in Chennai, India, he began working for BioWorld in 2018, taking on the database management role in early 2019.

Liz Hollis is a staff writer for BioWorld MedTech. She has covered the medical device and pharmaceutical industries for the past decade. She joined Clarivate Analytics in January 2017 as a medical/regulatory writer with Cortellis, covering FDA advisory committee meetings and workshops. She previously worked at FDAnews, the Association for the Advancement of Medical Instrumentation and Fiercemarkets.

Jihyun Kim covers the pharmaceutical and medical device business scenes in South Korea and Japan for BioWorld and BioWorld MedTech. As a writer, she tries to find out how medical products and regulations affect people's lives. Kim formerly worked as a writer and broadcaster in Seoul, focusing on Korea's medical policies and drug safety issues. She worked for Korea Exposé, Weekly Dong-A and SBS Radio in Korea

Lee Landenberger is a longtime health care journalist, having been a reporter, editor and executive in Ohio, Florida and Georgia. He won awards from the Associated Press, the Society of Professional Journalists and the Specialized Information Publishers Association. He has also overseen continuing education programs for health care practitioners, including physicians and nurses. Landenberger covers the development of biopharmaceuticals and the businesses that back the therapeutic candidates for BioWorld.

Stacy Lawrence has been covering the business and science of innovation for more than 20 years. She specializes in covering med tech and biotech, currently contributing regularly to BioWorld MedTech. Lawrence has been published in a variety of mainstream publications including MIT Technology Review, Wired and New Scientist, as well as industry resources such as Nature Biotechnology, Elsevier, BioCentury and FierceBiotech.

Elise Mak has been a staff writer for BioWorld, BioWorld Asia and BioWorld MedTech since 2018. She is based in Hong Kong and Beijing to cover the latest biotech developments and innovations in Asia, with a focus on Greater China. Mak has been following the regulatory updates, biopharmaceutical stocks, new companies and drug approvals to produce daily stories. She also covers conferences in Greater China and talks to industry insiders for first-hand insights.

Nuala Moran has been writing about science and technology for more than 30 years. Before joining BioWorld in 1996 she worked as deputy editor of Computer Weekly, managing editor of Nature, and innovation editor of the Independent on Sunday. She was also a regular contributor to the Financial Times between 1992 and 2003. In 1995 Moran was named as U.K. Technology Journalist of the Year and in 2016 won the Euroscience European Science Writer senior award. She contributes to BioWorld, BioWorld MedTech and BioWorld Science.

Brian Orelli has written for BioWorld since 2010. After earning his PhD from the University of Chicago, Orelli went on to a post-doc at the Ludwig Institute where he soon realized that hearing about other people’s work during lab meeting was the highlight of his week. He transitioned out of the lab and into writing where he gets to learn daily about new technologies.

Staff writer Randy Osborne's journalism career began in 1974, the year after he graduated high school, and includes hard news, features and investigative reporting for many general interest and alternative newspapers and magazines, as well as radio and television. He began covering biotech in 1997 at BioWorld, where he has held positions from staff writer to managing editor. He previously worked for Deloitte and Elsevier.

W. Todd Penberthy, PhD (biochemistry) started reporting science news for BioWorld in 2018. Previously he was a professor directing independent biomedical research before transitioning to writing in 2012. In addition to his work for BioWorld, Penberthy’s writing focus has been on continuing medical education with course development directed to physicians focused on guidelines and advances in clinical and biotechnology medicine. He regularly attends medical and scientific conferences.

Marie Powers remains as a contributing writer for BioWorld following her formal retirement in 2019. She continues to pen features, as she did before joining the team full-time in 2011 as staff writer. She was named news editor in 2015. Powers has logged more than 35 years on the health care beat, writing for specialty publications in biotechnology, neurology, orthopedic surgery, otolaryngology and managed care. She also served for nearly a decade as contributing editor to Technology Transfer Tactics. A longtime member of the Association of Health Care Journalists (AHCJ), in 2014 she was awarded an AHCJ-National Library of Medicine Fellowship.

Alfred Romann has 20 years of writing experience. His writing for BioWorld and BioWorld MedTech is focused on Asia and Latin America. He has worked across the Americas, Africa and Asia. Romann has written extensively for international publications and multinational organizations on issues of economics, finance and development.

Tamra Sami, based in Perth, Australia, has been writing about the biopharmaceutical and medical device industries for more than 17 years. She has expertise in Asia and emerging markets and international regulatory issues. She also covers product development, clinical trials and commercial strategy for both medical devices and biopharmaceuticals. Sami has more than 25 years of writing and editing experience and has covered a range of other industries including holistic health, transportation, wireless communications and travel. She writes for both BioWorld and BioWorld MedTech.

Based in Dublin, Cormac Sheridan has been writing about all aspects of the European and global biotechnology industry for more than 25 years, during which time he has been a correspondent for BioWorld and a regular contributor to Nature Biotechnology and many other publications. He has been a guest lecturer on the B.Sc. Genetics program at University College Cork (UCC) for more than 15 years.

Cornelia Zou has been a staff writer for BioWorld since 2013. Originally from Beijing, she has a strong understanding of the pharmaceutical industry in China and has covered many exclusive stories. She is particularly interested in regulatory reform and in new companies in the Chinese pharma space.

Production team

Andrea Applegate is the production editor for BioWorld MedTech. She is also responsible for posting social media content and producing reprints. Prior to joining the team in October 2016, she worked for the University of Georgia College of Agricultural and Environmental Sciences as an editor in the communications office.

Ann Marie Griffith joined BioWorld in 2017 as a production editor. She has worked in publishing for more than 25 years, starting as a features editor at a community newspaper in Pennsylvania before becoming the real estate editor at The Virginian-Pilot, a metro daily in Norfolk, Va. More recently, she coordinated content for two specialty magazines in Richmond, Va., and served as a development editor for an educational publishing company. She received a BA in communications from Penn State University.

Amanda Lanier joined the BioWorld team in 2004. She currently serves as a production editor for BioWorld, BioWorld Asia and BioWorld's market intelligence reports. Prior to joining BioWorld, Lanier worked as a features writer. She has a BA in communications from Oglethorpe University.

Business team

John Borgman, director of Commercial Competitive Intelligence at Clarivate Analytics, currently develops and leads growth strategies for commercial competitive intelligence information products. His work includes innovation and ongoing development for deals and valuation along with its globally respected epidemiology and all news offerings. Borgman pioneered development of TDR's (Timely Data Resources) globally respected epidemiology databases. For more than 15 years, Borgman has spent a significant amount of time with users of the database products to ensure that these products provide the optimum in flexibility, ease of use and therapeutic area coverage. Borgman sold TDR to Clarivate Analytics in 2013.